Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama

Cintra, Jane Rocha Duarte; Teixeira, Maria Teresa Bustamante; Diniz, Roberta Wolp; Gonçalves, Homero; Florentino, Thiago Marinho; Freitas, Guilherme Fialho de; Oliveira, Luiz Raphael Mota; Neves, Manoel Martins das; Pereira, Talita Carneiro Brandão; Guerra, Maximiliano Ribeiro

doi:10.1590/s0104-42302012000200013

Cited by 18 publications

(30 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Low nuclear grade tumors generally have lower growth rates [22]. Thus, our data suggest that FSTL3 expression may be more abundant in the slower proliferating tumors, challenging our previous assumption that this protein would contribute to human breast cancer growth.…”

Section: Discussioncontrasting

confidence: 55%

See 1 more Smart Citation

Prognostic value of follistatin-like 3 in human invasive breast cancer

Couto

Buzelin²,

Toppa³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Follistatin-like 3 (FSTL3) binds and inactivates activin, a growth factor involved with cell growth and differentiation. We have previously shown FSTL3 overexpression in invasive breast cancers, but its clinical relevance remained unexplored. Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer. A cohort of 154 women diagnosed with invasive breast cancer between 2008 and 2012 was followed up for 5 years. Tumor samples were processed by immunohistochemistry to detect FSTL3 expression in tumor epithelium. FSTL3 expression was classified semiquantitatively and tested for possible correlation with age, menopause status, stage, tumor histological type and grade, estrogen receptor, progesterone receptor, and HER2 expression. Survival plots with Kaplan-Mayer statistics were used to assess whether FSTL3 expression predicted disease-free survival. Our findings show that FSTL3 staining was unrelated to menopausal status, histological type, disease stage, or receptor profile. However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p<0.001) and with nuclear grade (p<0.01). The intensity of FSTL3 expression in the tumoral epithelium was not predictive of the disease-free survival (p = 0.991, log-rank test), even though the follow-up length and the study size were sufficient to detect a significant reduction in disease-free survival among women with stage III-IV compared to stage I-II disease (p<0.001). FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term.

show abstract

Section: Discussioncontrasting

confidence: 55%

“…This is interesting since small tumors are more often detected at screening programs and they also tend to be well differentiated (lower nuclear grade) [23]. This finding is in accordance with the stronger FSTL3 expression in tumors of lower nuclear grade, which usually grow at slower rates compared to those of higher nuclear grade [22]. …”

Section: Discussionmentioning

confidence: 65%

Prognostic value of follistatin-like 3 in human invasive breast cancer

Couto

Buzelin²,

Toppa³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…These tests are highly costly and complex, making it difficult to use regularly. A classification based on immunohistochemical markers, with similar but not identical criteria, is however feasible 6 .…”

Section: Introductionmentioning

confidence: 99%

“…The expression of estrogen (ER) and progesterone (PR) receptors and increased human epidermal growth factor receptor 2 (HER2) and proliferation index (Ki-67) are the immunohistochemical parameters used in this alternative classification 7 . Analogous to molecular classification, tumors are divided into luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-overexpressed and triple-negative 8 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical profile of breast cancer subtypes in patients seen at Napoleão Laureano Hospital, Paraíba, Brazil

Pinheiro¹,

Torres²,

Paz³

2019

Mastology

View full text Add to dashboard Cite

Objetivo: Determinar o perfil dos subtipos moleculares dos carcinomas invasivos de mama entre mulheres que realizaram o estudo imuno-histoquímico de maio 2013 a dezembro de 2014, no Hospital Napoleão Laureano, Paraíba, além de caracterizar a idade média ao diagnóstico e descrever os percentuais das seguintes variáveis: receptor de estrogênio e de progesterona, fator de crescimento epidérmico humano do tipo 2 e índice mitótico (Ki-67). Método: Estudo retrospectivo, ecológico, a partir da base de dados secundários do Laboratório de Anatomia Patológica do Hospital Napoleão Laureano. A população foi composta de 683 casos de carcinoma invasivo da mama, com estudo imuno-histoquímico realizado nessa instituição entre maio de 2013 e dezembro de 2014. Resultados: Dos 683 pacientes, foram excluídos 46 por apresentarem positividade para fator de crescimento epidérmico humano do tipo 2 inconclusiva (++), totalizando 637 casos contabilizados. Quinhentas e cinqüenta e seis pacientes (87,28%) eram RESUMO ABSTRACTObjective: To determine the profile of molecular subtypes of invasive breast carcinomas among women who underwent immunohistochemical study from May 2013 to December 2014, at Hospital Napoleon Laureano, Paraiba, Brazil, to characterize the mean age at diagnosis and describe the percentage of the following variables: estrogen and progesterone receptors, human epidermal growth factor 2 and proliferation index (Ki-67). Method: retrospective ecological study using the secondary databases at Hospital Napoleon Laureano Pathology Laboratory. The population consisted of 683 cases of invasive breast carcinoma with immunohistochemical study in this institution between May 2013 and December 2014. Results: Of the 683 patients, 46 were excluded because they presented inconclusive results for human epidermal growth factor 2 (++), totaling 637 recorded cases. Five hundred and fifty-six (87.28%) were 40 or older, and 81 (12.72%) under 40 years old. As for estrogen and progesterone receptor, 452 patients (70.96%) were positive for both receptors, while 185 (29.04%) showed no positivity. Four hundred and sixty-eight women (73.47%) did not show overexpressed human epidermal growth factor 2, while 169 (26.53%) did. The percentage of Ki-67 showed 474 individuals (74.41%) with a high proliferation index and 163 (25.59%) with a low index. The molecular subtypes showed the following prevalence: luminal A (143 cases; 22.45%), luminal B (250 cases; 39.25%), luminal B-enriched (113 cases; 17.84%), HER2 (57 cases; 8.95%) and triple-negative (74 cases; 11.62%). Conclusion: This study supported the notion of regional differences in the profile of breast tumors, since it showed a greater prevalence of triple-positive carcinomas and lower frequency of triple-negative tumors compared to studies of other Brazilian regions.

show abstract